Nanette H. Bishopric, M.D.Curriculum Vitae

Curriculum VitaE

1.Date: April 30, 2007

PERSONAL

2.Name:Nanette Hahr Bishopric, M.D., F.A.C.C., F.A.H.A.

3.Home Phone:Private

4.Office Phone:305-243-6775

5.Home Address: Private

6.Academic Rank:Professor, June 1, 2004

Tenured, June 1, 2002

7.Primary Department:Molecular and Cellular Pharmacology

8.Secondary Departments:Medicine and Pediatrics

Member, Sylvester Cancer Center

Faculty, John T. Macdonald Center for Medical Genetics

9.Citizenship:U.S.

10.Visa Type:N/A

HIGHER EDUCATION

11.Institutional:

1969-1973B.A., Magna Cum Laude, Music (Performance)

Duke University, Durham, North Carolina

1974-1975Cell Biology, Massachusetts

Institute of Technology, Cambridge, Massachusetts

1975-1979M.D., Duke University School of Medicine

Durham, North Carolina

12.Non-Institutional:

A.Clinical Training

1979-1980University of Florida, Gainesville, FL

Intern, Dept. of Medicine (Dr. James E. McGuigan, Chairman)

1980-1981Duke University, Durham, North Carolina

Fellow in Hematology/Oncology (Dr. Wendell Rosse, Chief)

1981-1983University of Florida, Gainesville, Florida

Assistant Resident, Dept. of Medicine (Dr. James E. McGuigan, Chairman)

1983-1985University of California at San Francisco

Clinical Fellow in Cardiology (Dr. William Parmley, Chief)

13.Certification

1983American Board of Internal Medicine

1985American Board of Internal Medicine (Cardiology)

1992National Board Examination Part III re-certification

Medical Licensure (active): State of California #G50082; State of Florida #37475

EXPERIENCE

14.Academic

1988-1989Instructor in Medicine, University of California at San Francisco

1989-1996Assistant Professor of Medicine, University of California at San Francisco

1992-1996Clinical Assistant Professor of Medicine, Stanford University

1996-2004Associate Professor of Pharmacology and Medicine, University of Miami, Miami, Florida

1998-presentDirector, UM-MHRI Cardiovascular Genetics Program

2002-2007Associate Professor of Pediatrics, University of Miami, Miami, Florida

2004-presentProfessor of Molecular and Cellular Pharmacology, University of Miami, Miami, Florida

2004-presentProfessor of Medicine, Division of Cardiology, University of Miami, Miami, Florida

2004-presentProfessor of Pediatrics, University of Miami, Miami, Florida

  1. Non-Academic

Hospital Appointments:

2005-presentCedars Medical Center, Staff Physician

1999-presentJackson Memorial Hospital, Staff Physician UMMG; Teaching

1989-1991Consulting Molecular Biologist, SRI International, Menlo Park, California

1992-1996Senior Molecular Biologist, Life Sciences Division

1992-1997Consultant in Health Sciences, Business and Policy Group

SRI International, Menlo Park, California

Representative Consulting Projects:

Consultant, modeling the market diffusion of a new antithrombotic agent in the U.K. (1996)

Consultant, identification of novel technologies for licensing and acquisition (for major U.S. pharmaceutical client, 1997-1998)

Consultant, assessment of biological targets for lead development compounds (for major U.K. pharmaceutical client, 1996-1997)

Expert witness for the defense, major US pharmaceutical company, drug outcomes litigation (2004-2007)

Expert witness for the defense, US generic drug manufacturer, drug outcomes litigation (2006)

Expert witness for the defense, major US pharmaceutical company, drug outcomes litigation (2005-present)

Expert witness, tobacco-related diseases litigation (2007-)

16.Military

N/A

PUBLICATIONS

  1. Books, reviews and monographs:
  1. Webster KA and Bishopric NH. Cardiomyocyte apoptosis. In: The Heart in Biology and Disease, ed. E. Bittar, Vol. 16 (2007, in preparation).
  1. Jain S, Rodrigues CO, Webster KA, Bishopric NH (2007). New therapeutic targets to prevent cardiomyocyte apoptosis. J. Pharmacol Exp Therap, in press.
  1. Bishopric NH, Andreka P and Webster KA. Apoptosis and risk with the use of calcium antagonists. In: Calcium Channel Antagonists in Clinical Medicine, 3rd edition, ed. M. Epstein. Hanley and Belfus, Philadelphia, 2002.
  1. Webster KA, Prentice H, Bishopric NH. Redox regulation of zinc finger transcription factors. In: Antioxidants and Redox Signaling, 3: 535-548, 2001.
  1. Webster KA, Discher DJ, Hernandez O, Yamashita K, and Bishopric NH. A glycolytic pathway to apoptosis of hypoxic cardiac myocytes: molecular pathways of increased acid production. In: Oxygen Sensing: Molecules to Man, S. Lahiri & N. Prabhakar, eds., Kluwer. Academic Press, London, UK, 2000.
  1. Webster KA and Bishopric NH. Molecular aspects and gene therapy prospects for diastolic failure. In: Cardiology Clinics, SJ Kovacs, ed., W.B. Saunders & Co. volume 18(3): 621-635, 2000.
  1. Webster KA, Discher DJ and Bishopric NH. Induction of proto-oncogenes and lipid second messengers in hypoxic cardiac myocytes. In: Hypoxia and Molecular Medicine, J. R. Sutton, C. S. Houston and G. Coates, eds. Queen City Printers, Inc., Burlington VT, pp 98-111, 1993
  1. Bishopric NH, Wade R, Gahlmann R and Kedes LH. Gene expression during skeletal and cardiac muscle development. In: The Heart and Cardiovascular System, second edition, H.A. Fozzard et al., eds. Raven Press, Ltd., New York, pp 1587-1598, 1992
  1. Bishopric NH, Long CS, Waspe LE, Simpson PC and Ordahl CP (1989). The molecular biology of cardiac myocyte hypertrophy. Studies using a cell culture model. In: Cellular and Molecular Biology of Muscle Development, UCLA Symposia Vol. 93 (New Series), L. H. Kedes and F. E. Stockdale, eds., Alan R. Liss, Inc., New York, pp 399-412, 1989
  1. Simpson PC, Bishopric NH, Coughlin SR, Karliner J, Ordahl CP, Starksen N, Tsao T, White N and Williams LT: Dual trophic effects of the ß1-adrenergic receptor in cultured neonatal rat heart muscle cells. J Mol Cell Cardiol 18 (Suppl 5): 45, 1986
  1. Bishopric NH, Mehta J and Mehta P. Platelet activation and platelet-suppressive drugs. In: Platelets and Prostaglandins in Cardiovascular Disease, Mehta J and Mehta P, eds., Futura Publishing Co., Mt. Kisco, NY: 1981.

18.Juried or refereed journal articles or exhibitions:

(in preparation or submitted)

  1. Shehadeh L, Sharma S., Pessanha M, Wei JQ, Webster KA, and Bishopric NH (2007). Cardiac myocyte p300 levels regulate angiogenesis during myocardial hypertrophy through Sox4. In preparation.
  1. Bishopric NH, Hilfiker D, Drexler H, Dzau V, Sugden P (2007). Facts about factors: paracrine signalling by stem cells in cardiac repair. In preparation.
  1. Rodrigues CO, Wei JQ, Li J, Llanos A, Webster KA, Bishopric NH (2007). Accelerated aging in a mouse model of p300 histone acetylase deficiency. In preparation.
  1. Papapetropoulos S et al. Gene expression of MT1 & MT2 receptors in Parkinson’s disease human post mortem brain (2007). J Pineal Res, submitted.
  1. Wei JQ, Mitrani J, Pessanha M, Shehadeh L, Slepak TI, Webster KA and Bishopric NH (2007). Stoichiometric regulation of cardiac hypertrophy by acetyltransferase p300. Genes Devel, submitted.
  1. Wilson A, Shehadeh LA, Gosink M, Tsinoremas NF, Bishopric NH and Webster KA (2007). Age and maturity confer distinctive gene expression profiles in murine bone marrow mesenchymal stem cells. Stem Cell, submitted.

(in press or published)

  1. Ley JJ, Prado R, Wei JQ, Bishopric NH, Ginsberg MD (2007). Neuroprotective antioxidant STAZN protects against myocardial ischemia/reperfusion injury. Biochem. Pharmacol, in press.
  1. Graham R, Thompson JW, Wei JQ, Bishopric NH and Webster KA (2007). Regulation of Bnip3 death pathways by calcium, phosphorylation and hypoxia-reoxygenation. Antiox Redox Signal, 9(9):1309-16
  1. Tran TH, Andreka P, Rodrigues CO, Webster KA and Bishopric NH (2007). Jun kinase delays caspase-9 activation by interaction with the apoptosome. J Biol Chem, 282(28):20340-50. Epub 2007 May 4.
  1. Rodrigues CO, Shehadeh L, Webster KA and Bishopric NH (2007). Myocyte deficiency as a target in the treatment of cardiomyopathy. Progress in Pediatric Cardiology, in press.
  1. Shehadeh LA, Bishopric NH, Wilson A, Gosink M, Tsinoremas N, and Webster KA (2007). Immune remodeling of mesenchymal stem cells during osteoblastic differentiation. Nature Biotechnology Short Reports, in press.
  1. Papapetropoulos S, Adi N, Shehadeh L, Mash D, Bishopric NH. (2007). Expression of -synuclein mRNA in Parkinson’s Disease. Movement Disorders, 22(7):1057-9.
  1. Frazier DP, Wilson A, Dougherty C, Li, H, Bishopric NH, Webster KA (2007). PKC-delta and TAK-1 are intermediates in the activation of c-Jun N-terminal kinase (JNK) by hypoxia-reoxygenation. Am J Physiol Heart Circ Physiol. 292(4):H1675-84. Epub 2007 Jan 5.
  1. Miller TE, You L, Myerburg RJ, Benke PJ, Bishopric NH (2007). Whole blood RNA offers a rapid, comprehensiveapproach to genetic diagnosis of cardiovascular diseases. Genetics in Medicine 9(1): 23-33.
  1. Webster KA, Graham RM, Thompson JW, Spiga MG, Frazier DP, Wilson A, Bishopric NH (2006). Redox stress and the contributions of BH3-only proteins to infarction. (2006) Antioxid Redox Signal 8(9-10):1667-1676.
  1. Frazier DP, Wilson A, Graham RM, Thompson JW, Bishopric NH, Webster KA (2006). Acidosis regulates the stability, hydrophobicity, and activity of the BH3-only protein Bnip3. Antioxid Redox Signal. 8(9-10):1625-1634.
  1. Rodrigues CO, White EL, King ML, Nerlick S, Bishopric N, and Cleveland JL (2006). A MYC-twist-slug regulatory circuit directing neural crest determination affects angiogenesis. Nature Biotechnology Short Reports, 17:78
  1. Spiga M-G, Layman H, Wilson AD, Jia Y, Bishopric NH, Andreopoulos FM, and Webster KA (2006). Delivery of VEGF165 with hypoxia-regulated adeno-associated virus (AAV) serotype 9 produces stable conduction vessels in mouse ischemic limbs. Nature Biotechnology Short Reports, 17:85.
  1. Pessanha M, Wei JQ, Shehadeh L, Faysal J, Webster KA, and Bishopric NH (2006). Cardiac myocyte p300 levels regulate myocardial angiogenesis. Nature Biotechnology Short Reports, 17:87.
  1. Bishopric, NH (2005). Evolution of the heart from bacteria to man. Annals of the New York Academy of Sciences 1047:13-29.
  1. Webster KA, Graham RM, Bishopric NH (2005). BNip3 and signal-specific programmed death in the heart. J Mol Cell Cardiol 38(1):35-45.
  1. Turner MS, Haywood GA, Andreka P, You L, Martin PE, Evans WH, Webster KA, Bishopric NH (2004). Reversible connexin 43 dephosphorylation during hypoxia and reoxygenation is linked to cellular ATP levels. Circ Res 95(7):726-733.
  1. Graham RM, Frazier DP, Thompson JW, Haliko S, Li H, Wasserlauf BJ, Spiga MG, Bishopric NH and Webster KA (2004). A unique pathway of cardiac myocyte death cased by hypoxia-acidosis. J Exp Biol 207(18):3189-3200.
  1. Andreka P, Tran T, Webster KA, Bishopric NH (2004). Nitric oxide and promotion of cardiac myocyte apoptosis. Molecular and Cellular Biochemistry 263:35-53.
  1. Andreka P, Nadhazi Z, Muzes G, Szantho G, Vandor L, Konya L, Turner MS, Tulassay Z and Bishopric NH (2004). Possible therapeutic targets in cardiac myocyte apoptosis. Current Pharmaceutical Design 10(20):2445-2461.
  1. Miller TE, Estrella E, Myerburg RJ, Garcia de Viera J, Moreno N, Rusconi P, Ahearn ME, Baumbach L, Kurlansky P, Wolff G and Bishopric NH (2004). Recurrent third trimester fetal loss and maternal mosaicism for long-QT syndrome. Circulation 109(24):3029-3034.
  1. Webster KA, Bishopric NH (2003). Apoptosis inhibitors for heart disease. Circulation 108(24):2954-6.
  1. Myerburg RJ and Bishopric NH (2003). Transplantation of stem cells to the heart: are there risks counterbalancing anticipated benefits? J Cardiovasc Electrophysiol 14(8):849-50.
  1. Kubasiak L, Hernandez L, Bishopric NH and Webster KA (2002). Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc Natl Acad Sci USA 99:12825-12930.
  1. Bishopric NH and Webster KA (2002). Preventing apoptosis with thioredoxin: ASK me how. Circ Res90(12):1237-1239.
  1. Graham R, Bishopric NH and Webster KA. (2002) Gene and cell-based therapy for heart disease. IUBMB Life54(2):59-66.
  1. Bishopric NH. A Thousand Times NO. (2002) J Mol Cell Cardiol 34; 601-606.
  1. Andreka P, Aiyar N, Olson LC, Wei JQ, Turner MS, Webster KA, Ohlstein EH, and Bishopric NH. (2002) Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation 105:2429-2434.
  1. Dougherty C, Kubasiak LA, Prentice H, Andreka P, Bishopric NH and Webster KA. (2002) Activation of c-Jun N-terminal kinase promotes survival of cardiac myocytes after oxidative stress. Biochem J 362:561-571.
  1. Bishopric NH (2002). Angiotensin signaling and apoptosis in the neonatal heart: necessary evils? Pediatric Res 52(3):322-4.
  1. Bishopric NH, Andreka P, Slepak T, and Webster KA (2001). Molecular mechanisms of apoptosis in the cardiac myocyte. Curr Opinion in Pharmacology 2: 141-150.
  1. Andreka P, Nadhazi Z, Muzes G, Bishopric NH (2001). Molecular regulation of myocardial apoptosis. (Review in Hungarian) Orv Hetil 142:1717-1724.
  1. Andreka P, Zang J, Dougherty C, Slepak T, Webster KA, and Bishopric NH (2001) Cytoprotection by Jun kinase during nitric oxide-induced cardiac myocyte apoptosis. Circ Res 88: 305-312.
  1. Yamashita Y, Discher DJ, Hu J, Bishopric NH, and Webster KA (2001). Molecular regulation of the endothelin-1 gene promoter by hypoxia: contributions of HIF-1, AP-1, GATA-2, and CBP/p300. J Biol Chem 276:12645-12653.
  1. Yamashita Y, Kajstura J, Discher DJ, Wasserlauf BJ, Bishopric NH, Anversa P and Webster KA (2001). Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts over-expressing IGF-1. Circ Res 88: 609-614.
  1. Webster KA, Prentice H, Bishopric NH (2001). Oxidation of zinc finger transcription factors: physiological consequences. Antioxid Redox Signal 3:535-548.
  1. Slepak T, Webster KA, Prentice H, O’Dowd A, Hicks M and Bishopric NH (2001). Control of cardiac-specific transcription by p300/CBP through myocyte enhancer factor-2D. J Biol Chem 276: 7575-7585.
  1. Leri A, Fiordaliso F, Setoguchi M, Limana F, Bishopric NH, Kajstura J, Webster KA and Anversa P (2000). Inhibition of p53 function prevents renin-angiotensin system activation and stretch-mediated myocyte apoptosis. Am J Pathology 157:843-857.
  1. Hernandez O, Discher DJ, Bishopric NH and Webster KA (2000). Rapid Activation of neutral sphingomyelinase by hypoxia-reoxygenation of cardiac myocytes Circ Res 86:198-204.
  1. Webster KA, Discher DJ, Kaiser S, Hernandez O, Sato B and Bishopric NH (1999). Hypoxia-activated apoptosis of cardiac myocytes requires a pH shift and is independent of p53. J Clinical Invest 104: 239-252.
  1. Discher DJ, Bishopric NH and Webster KA (1999). High Frequency Rearrangement of a Multiple Copy Enhancer in Plasmid Vectors: Practical Considerations. Biotechniques 26:1026-1030.
  1. Webster KA, Discher DJ, Kaiser S, Sato B, Zang J, Hernandez O and Bishopric NH (1999). Induction of apoptosis by hypoxia requires reoxygenation or acidosis and is independent of p53. J Clin Invest 104: 239-252.
  1. Ing D, Zang J, Dzau V, Webster KA and Bishopric NH (1999). Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak and Bcl-x. Circ Res 84: 21-33.
  1. Webster KA and Bishopric NH (1998). Adaptaciones de miocitos cardiacos prematuros a la hipoxia, isquemia, y reoxígenación Revista Chilena de Cardiología Vol. 14.
  1. Discher DJ, Bishopric NH, Wu XS, Petersen C and Webster KA (1998). Hypoxia regulates -enolase and pyruvate kinase-M promoters by modulating Sp1/Sp3 binding to a conserved GC element. J Biol Chem 273: 26087-26093.
  1. Gullestad L, Haywood G, Aass H, Ross H, Yee G, Geiran O, Kjekshus J, Simonsen S, Bishopric NH and Fowler M (1998). Expression of angiotensin II receptor subtypes in heart transplant recipients. Cardiovasc Res 38: 340-347.
  1. Prentice H, Bishopric NH, Hicks MN, Discher DJ, Wu XS, Wylie AA and Webster KA (1997). Regulated expression of a foreign gene targeted to the ischaemic myocardium. Cardiovasc Res 35(3): 567-574.
  1. Webster KA, Discher DJ and Bishopric NH (1997). Models of Heart Disease: Early and late gene responses to hypoxia, ischemia, and reoxygenation. Acta Andina 6:89-107.
  1. Wu CF, Bishopric NH, and Pratt RE (1997). A sensitive nonradioactive method for the determination of internucleosomal cleavage associated with apoptosis. Biotechniques 23(5): 839-843.
  1. Wu C-F, Bishopric NH and Pratt RE (1997). ANP induces apoptosis in rat cardiac myocytes. J Biol Chem 272: 14860-14866.
  1. Eschenhagen T, Remmers U, Scholz H, Wattchow J, Weil J, Zimmerman W, Schäfer H, Bishopric NH, Wakatsuki T and Elson EL (1997). Three dimensional reconstitution of embryonic cardiomyocytes in a collagen matrix: a new heart muscle model system. FASEB J 11:683-694.
  1. Bishopric NH, Zeng GQ, Sato B and Webster KA (1997). Adenovirus E1A inhibits cardiac myocyte-specific gene expression through its amino terminus. J Biol Chem 272: 20584-20594.
  1. Ellison K, Bishopric N, Webster K, Morishita R, Gibbons GH, Kaneda Y, Sato B and Dzau V (1996). Enhanced effectiveness of HVJ mediated gene transfer into cultured rat neonatal cardiac myocytes. J Mol Cell Cardiol 28: 1385-1399.
  1. Haywood GA, Tsao PS, von der Leyen HE, Mann MJ, Keeling PJ, Trindade PT, Lewis NP, Byrne CD, Rickenbacker PR, Bishopric NH, Cooke JP, McKenna WJ and Fowler MB (1996). Expression of inducible nitric oxide synthase in human heart failure. Circulation 93: 1087-1094.
  1. Wu XS, Bishopric NH, Discher DJ, Murphy BJ and Webster KA (1996). Physical and functional sensitivity of zinc finger transcription factors to redox change. Mol Cell Biol 16(3): 1035-1046.
  1. Webster KA, Bodí I, Wu X, Discher D, and Bishopric NH (1995). Regulation of the endothelin-1 gene by hypoxia is endothelial cell-specific and requires tyrosine kinase. Cardiovasc Res 30: 975-984.
  1. Webster KA, Discher D and Bishopric NH (1995). Cardioprotection in an in vitro model of hypoxic preconditioning. J Mol Cell Cardiol 27: 453-458.
  1. Webster KA, Discher DJ and Bishopric NH (1994). Regulation of Fos and Jun immediate-early genes by redox or metabolic stress in cardiac myocytes. Circ Res 74: 679-686.
  1. Webster KA, Discher DJ and Bishopric NH (1993). Induction and nuclear accumulation of Fos and Jun proto-oncogenes in hypoxic cardiac myocytes. J Biol Chem 268: 16852-16859.
  1. Webster KA, Bodi I, Discher D, McNamara JP, Tracy M and Bishopric NH (1993). Negative lusitropy and abnormal calcium handling in hypoxic cardiac myocytes exposed to the calcium sensitizer EMD53998. J Mol Cell Cardiol 25: 747-751.
  1. Bishopric NH, Jayasena V, and Webster KA (1992). Positive regulation of the skeletal -actin gene by Fos and Jun. J Biol Chem 267: 25535-25540.
  1. Bishopric NH, Sato B and Webster KA (1992). -adrenergic regulation of a myocardial actin gene via a cyclic AMP-independent pathway. J Biol Chem 267: 20932-20936.
  1. Webster KA and Bishopric NH (1992). Molecular regulation of cardiac myocyte adaptations to chronic hypoxia. J Mol Cell Cardiol 24: 741-752.
  1. Sartorelli V, Hong NA, Bishopric NH and Kedes LH (1992). Myocardial activation of the human cardiac -actin promoter by helix-loop-helix proteins. Proc Natl Acad Sci 89: 4047-4051.
  1. Bishopric NH and Kedes LH (1992). Adrenergic regulation of the skeletal -actin gene promoter during myocardial cell hypertrophy. Proc Natl Acad Sci 88: 2132-2136.
  2. Bishopric NH, Simpson PC and Ordahl CP (1987). Induction of the skeletal -actin gene in 1-adrenoceptor mediated hypertrophy of rat cardiac myocytes. J Clin Invest 80: 1194-1199.
  3. Starksen NF, Simpson PC, Bishopric NH, Coughlin SR, Lee WMF, Escobedo JA and Williams LT (1986). Cardiac myocyte hypertrophy is associated with c-myc proto-oncogene expression. Proc Natl Acad Sci 83: 8348-8350.
  4. Bishopric NH, Cohen HJ and Lefkowitz RJ (1980). -adrenergic receptors in lymphocyte subpopulations. J Allergy Clin Immunol 65: 29-33.
  5. Newman, KD, Williams LT, Bishopric NH and Lefkowitz RJ (1978). Identification of the platelet 1-adrenergic receptor by direct binding of (3H)-dihydroergocryptine. J Clin Invest 61: 395-402.

19.Other works, publications and abstracts:

Abstracts (selected).

  1. Rodrigues CO, Shehadeh LA, Calero K, Bishopric NH (2007). Transcriptional variability in cardiac stem cell clones. 4th Annual Symposium of the American Heart Association Council on Basic Cardiovascular Sciences, July 30 - August 2, 2007, Keystone Conference Center, Keystone, Colorado.
  2. Ali MAM, Sung MM, Tran T, Crawford B, Rosenfelt CS, Sawicki G, Bishopric NH, Schulz R (2007).Inhibitors of matrix metalloproteinases prevent H2O2-mediated cardiac myocyte membrane permeabilization and death. Western Pharmacological Society, Banff, Alberta, Canada, March 2007.
  3. Wei JQ, Llanos A, Rodrigues C, Steen D, Webster KA and Bishopric NH (2006). Cardioprotection by p300 during myocardial ischemia-reperfusion and infarction in vivo. Circulation 114 (18): II-98.
  4. Thompson JW, Graham RM, Bishopric NH and Webster KA (2006). Programmed death by hypoxia-acidosis involves BNip3- and ERK-dependent activation of histone acetyltransferase (HAT) and genomic reprogramming. Circulation 114 (18): II-296.
  5. Wierenga KJ, Miller TE, Bishopric NH, Benke PJ (2006). A novel splice site mutation associated with Barth syndrome. Presented at American College of Medical Genetics 2006 Annual Meeting. Online at
  6. Webster KA, Spiga M-G, Wilson AA, Bishopric NH, Eton D, Jia Y, Cesar L, Haliko S, Yu H, Lieber BB, Laymen H, Andreopoulos FM, Wei J, Yeasky T. Combination cell and gene therapy for peripheral ischemia using myoblasts and stem cells engineered with conditionally sliced genes. Miami-Nature Biotechnology Winter Symposia on Angiogenesis in Cancer and Vascular Disease, Feb. 4-8, 2006. Nature Biotechnology Short Reports, Vol 17.
  7. Tran T, Andreka P Webster KA and Bishopric NH (2005). Cytoprotection by Jun kinase is mediated through direct inhibition of the apoptosome. American Heart Association National Meeting, November 2005; Circulation,
  8. Thompson JW, Graham RM, Bishopric NH and Webster KA (2005). BNip3 promotes nuclear translocation of mitochondrial and lysosomal DNAses: protection from genomic fragmentation by a HH-4 peptide or calpain inhibitors. Circulation 112 (17): II-285.
  9. Baumbach L, Miller T, Cocilova S, Travers H, Elliott S, Mont E, Myerburg R, Bishopric N (2005). Genetic Complexities of Molecular Diagnosis for Ventricular Arrhythmias. American Society of Human Genetics 55th Annual Meeting Abstracts (Salt Lake City, Utah), October 25-29, 2005, in press.
  10. Shehadeh L, Wei JQ, Liebovitch L, Jirsa V, Fallahi M, Tsinoremas N, Prentice H, Bishopric N. Transcription Factor Networks in Cardiac Hypertrophy. BioFlorida Annual Conference, “Building the Vision,” Delray Beach, FL presented October 24-25, 2005.
  11. Miller TE, You L, Benke PJ, Bishopric N (2005). Rapid Screening of Complex Genetic Disorders Associated with Heart Disease Using Direct Whole Blood RT-PCR. J Am Coll Cardiol 45(3) Suppl A: 323A, #1142-245. (ACC 3/8/2005)
  12. Wei JQ, Mitrani J, Llanos A, Webster KA, Bishopric (2005). Role of the Chromatin Remodelling Enzyme p300 In Heart Failure Progression and Survival. J Am Coll Cardiol 45(3) Suppl A: 174A, #1160-147. (ACC 3/8/2005)
  13. TE Miller, TV Pham, MJ Smets, L You, A Bassett, P Kurlansky, LL Baumbach-Reardon, RJ Myerburg, NH Bishopric (2004). Novel Mutations (S338F and F339S) in Cardiac KvLQT1 S6 Domain Hinder KvLQT1 – KCNE1 Co-Assembly. Circulation 110(17): III-16 #67. (AHA 11/2004)
  14. Webster KA, Gounis MJ, Spiga M.-G., Graham RM, Haliko S, Wilson A, Lieber BB, Bishopric NH and Wakhloo NH (2004). Optimized therapeutic angiogenesis for peripheral ischemia using stem cells transduced with an ischemia-regulated conditionally silenced AAV. Late-Breaking Developments in Stem Cell Biology and Cardiac Growth Regulation, America Heart Association National Meeting, New Orleans, LA 11/8/04.
  15. Li HF, Bishopric NH, Webster KA (2004). C-Jun N-terminal Kinase (JNK) promotes apoptosis at reperfusion under energy-limiting conditions by phosphorylating IRS-1 and blocking insulin signaling to Akt/PKB. Circulation 110(17): III-58 #268. (AHA 11/2004)
  16. L Baumbach, T Miller, H Travers, L You, ME Ahearn, W Lanier, E Estrella, S Elliott, R Myerburg, N Bishopric (2004.